By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VentiRx Pharmaceuticals, Inc. 

1191 Second Avenue
Suite 1105
Seattle  Washington  98101  U.S.A.
Phone: 206-689-2259 Fax: n/a


Company News
VentiRx Pharmaceuticals, Inc. Granted Orphan Drug Designation In The European Union For Motolimod In The Treatment Of Ovarian Cancer 4/27/2015 6:33:53 AM
Seattle Startup VentiRx Pharmaceuticals, Inc. Lands 19.3 Million 9/24/2014 6:30:09 AM
VentiRx Pharmaceuticals, Inc. Provides Corporate And Clinical Update 9/2/2014 1:42:22 PM
VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted For Motolimod (VTX-2337), A Novel Immunotherapy For Women With Ovarian Cancer 9/2/2014 1:40:43 PM
VentiRx Pharmaceuticals, Inc. Announces The Completion Of Patient Enrollment In Randomized, Placebo-Controlled Phase 2 Trial Of VTX-2337 In Combination With Pegylated-Liposomal Doxorubicin In Platinum-Resistant Ovarian Cancer 4/17/2014 12:08:52 PM
VentiRx Pharmaceuticals, Inc. Presents Phase 1 Data On VTX-2337 At 2014 Multidisciplinary Head And Neck Cancer Symposia 2/20/2014 9:48:38 AM
VentiRx Pharmaceuticals, Inc. Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination With Cetuximab and Chemotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 7/2/2013 9:55:06 AM
VentiRx Pharmaceuticals, Inc. Release: Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 American Society of Clinical Oncology Annual Meeting Shows Early Activity in Ovarian Cancer 6/3/2013 8:24:43 AM
VentiRx Pharmaceuticals, Inc. Appoints James Kyle Bryan, M.D. as Chief Medical Officer 4/23/2013 7:38:54 AM
VentiRx Pharmaceuticals, Inc. Initiates Randomized, Placebo-Controlled, Phase 2 Trial of VTX-2337 in Patients With Recurrent or Persistent Ovarian Cancer 10/22/2012 9:49:19 AM